Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE-BDT in Metastatic Breast Cancer
NCT07340541Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Feb 2026
- Primary completion
- Jun 2031
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib, everolimus and capecitabine in breast cancer (6 cohorts), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Intra-Individual Progression-Free Survival at 5 years. Started Feb 2026; status: recruiting.
02
Drugs
abemaciclibeverolimuscapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07340541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340541.